Richard McNally
Albany Medical College · 13 works · 222 citations · h-index 6
Top works
- Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer
- Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
- A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib
- A case of acute myelofibrosis with complex karyotypic changes: A type of myelodysplastic syndrome
- Results of a phase II trial of single-agent amrubicin (AMR) in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: An update
- Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy
- 9120 Second-line amrubicin vs topotecan in extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy: updated results of a randomized phase 2 trial
- Amrubicin (AMR) and cardiotoxicity in second-line treatment of small cell lung cancer (SCLC): A pooled analysis of left ventricular ejection fraction (LVEF) in two phase II trials
- Amrubicin (AMR) does not reduce LVEF with cumulative doses > 1000 mg/m(2) in 2nd-line treatment of small cell lung cancer (SCLC): A pooled analysis of two phase II trials
- PCN111 Evaluating Meaningful Change on the Lung Cancer Symptom Scale in Small Cell Lung Cancer: Results From a Phase III Clinical Trial
- Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). [2011 ASCO poster]
- 9121 Amrubicin monotherapy in patients with extensive disease small cell lung cancer (ED-SCLC) refractory to first-line platinum-based chemotherapy: final results of a phase 2 trial
- Phase I study to assess pharmacokinetics (PK), QT/QTc effect, and safety of amrubicin in patients (pts) with advanced solid tumors.